|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Zoloft
|
|
gptkbp:activities
|
gptkb:selective_serotonin_reuptake_inhibitor_(SSRI)
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1991
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Zoloft
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
MAO inhibitors
hypersensitivity to sertraline
|
|
gptkbp:dosage_form
|
150 mg daily
200 mg daily
100 mg daily
50 mg daily
|
|
gptkbp:formulation
|
sertraline hydrochloride extended-release tablet
sertraline hydrochloride oral solution
sertraline hydrochloride oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sertraline hydrochloride
|
|
gptkbp:ingredients
|
C17 H17 Cl2 N
|
|
gptkbp:interacts_with
|
gptkb:beer
gptkb:warfarin
NSAI Ds
other SSR Is
|
|
gptkbp:is_atype_of
|
N06 A B06
|
|
gptkbp:is_available_on
|
generic medication
|
|
gptkbp:is_used_for
|
gptkb:historical_event
gptkb:post-traumatic_stress_disorder
anxiety disorders
obsessive-compulsive disorder
panic disorder
|
|
gptkbp:lifespan
|
24 hours
|
|
gptkbp:marketed_as
|
gptkb:Pfizer
|
|
gptkbp:metabolism
|
CY P2 C19
CY P3 A4
CY P2 B6
|
|
gptkbp:related_to
|
gptkb:microprocessor
mental health
anxiety
mood disorders
serotonin
|
|
gptkbp:side_effect
|
dizziness
nausea
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:type_of
|
79617-96-2
|